Evofem Biosciences (EVFM) Proxy Filing summary

Executive summary

• The proxy filing details a proposed merger between Evofem Biosciences, Inc. and Aditxt, Inc., with Evofem becoming a wholly owned subsidiary of Aditxt upon closing, expected in the second half of 2025.

• The merger consideration for Evofem common shareholders is $1.8 million in cash, subject to adjustments for dissenting shares, and Series E-1 preferred shareholders will receive Aditxt Series A-2 convertible preferred stock.

• The transaction is subject to approval by Evofem and Aditxt shareholders, regulatory approvals, and satisfaction of other customary closing conditions, including the retirement of Evofem's senior secured notes.

• The merger agreement has been amended multiple times to adjust funding dates, investment amounts, and the outside closing date, now set for September 30, 2025.

Voting matters and shareholder proposals

• Shareholders are asked to vote on two proposals: (1) approval of the merger agreement and (2) authorization for the board to adjourn the meeting to solicit additional proxies if needed.

• The board recommends voting “FOR” both proposals.

• Approval of the merger requires a majority of the combined voting power of common and Series E-1 preferred stock, voting as a single class.

• Appraisal rights are available to dissenting shareholders under Delaware law.

Board of directors and corporate governance

• Post-merger, the surviving company’s officers will be Saundra Pelletier (CEO) and Ivy Zhang (CFO), with directors Saundra Pelletier, Amro Albanna, and Lisa Rarick.

• The current board is divided into three classes, with staggered terms and a mix of independent and executive directors.

• The board has the authority to fill vacancies and set the number of directors.